Abstract 4099
Background
The aim of this study was to analyze the safety and effectiveness of different preoperative preparation time in the neoadjuvant chemotherapy (SOX) regimen in patients with advanced gastric cancer.
Methods
From June 1 2010 to June 1 2017, 120 patients aged from 25 to 80 with clinical stage IIA-IIIC gastric cancer received neoadjuvant chemotherapy with S-1 and oxaliplatin and radical gastrectomy in Chinese PLA General Hospital. They were eligible for inclusion and they were randomly assigned to either the 3-weeks group, which received radical gastrectomy 3 weeks after neoadjuvant chemotherapy (n = 60), or the 5-weeks group, which received radical gastrectomy 5 weeks after neoadjuvant chemotherapy (n = 60). We compared short-term surgical outcomes between the two groups.
Results
There were no significant differences between the two groups regarding the clinical pathological characteristics. However, the 5-weeks group had less intraoperative blood loss (229 ml vs 240 ml, P = 0.031) and less Clavien-Dindo grade II to IV complications (P = 0.006) than the 3-weeks group. Baseline clinicopathologic characteristics, and short-term outcomes of the patients treated in the two groups were similar.
Conclusions
Patients with advanced gastric cancer undergoing advanced neoadjuvant chemotherapy after neoadjuvant chemotherapy require a certain amount of time to adjust and prepare for gastrectomy. Considering the general condition of the patients, the preoperative interval can be shortened and the efficacy can be improved.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Wangxinxin.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
1452 - RBP-Jκ in colon cancer cells facilitates tumor associated macrophages (TAMs)-induced cell metastasis by secreting CXCL11
Presenter: Meng jie Liu
Session: Poster Display session 2
Resources:
Abstract
2786 - Development of a living organoid biobank derived from colorectal cancer patients: towards personalized medicine
Presenter: Federica Papaccio
Session: Poster Display session 2
Resources:
Abstract
3351 - Microsatellite Instability Detection in Colorectal Cancer: 44-Center Comparison between the Idylla MSI Assay and Routine Molecular and Immunohistochemistry Tests on Formalin-Fixed Paraffin-Embedded Tissue
Presenter: Xavier Matias-guiu
Session: Poster Display session 2
Resources:
Abstract
4901 - Expression profile of EPHB3 and its prognostic significance in colorectal cancer progression (Running head: Prognostic value of EPHB3 in colorectal cancers)
Presenter: Bogun Jang
Session: Poster Display session 2
Resources:
Abstract
5030 - A pan-ErbB family inhibitor, AF8c, promotes apoptosis by DR5/Nrf2 activation via ROS in colorectal cancer cells
Presenter: Soyeon Jeong
Session: Poster Display session 2
Resources:
Abstract
5053 - Frequent BRAF, GNAS and SMAD4 mutations identified in Colorectal Mucinous Carcinomas
Presenter: Sun Mi Lee
Session: Poster Display session 2
Resources:
Abstract
5220 - Impact of CCL4 knockout using CRISPR Cas-9 technology on colorectal tumor progression
Presenter: Roba Barakat
Session: Poster Display session 2
Resources:
Abstract
5330 - Independent clinical validation of a gene expression profile to predict benefit of 5-FU in metastatic colorectal cancer
Presenter: Ida Buhl
Session: Poster Display session 2
Resources:
Abstract
5515 - WRN mutated Colorectal Cancer (CRC) is characterized by a distinct molecular and immunological profile
Presenter: Andreas Seeber
Session: Poster Display session 2
Resources:
Abstract
5716 - Mutation analysis of B2M gene in colorectal cancer patients with microsatellite instability
Presenter: Ivana Kašubová
Session: Poster Display session 2
Resources:
Abstract